ReviewInflammopharmacology2026
Drug repurposing against viral infections (2020-2025): clinical trials, computational strategies, and therapeutic interventions.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past five years, amid the escalating threat of viral outbreaks, drug repurposing has emerged as a pivotal strategy for rapidly deploying existing pharmacological agents against newly emerging infectious diseases. This review provides a comprehensive analysis of drug repurposing efforts targeting major viral infections between 2020 and 2025, with a particular focus on clinical trials and intervention strategies. The background and growing significance of drug repurposing are discussed in the context of the urgent global demand for accelerated antiviral development. Key viral infections, including SARS-CoV-2, monkey pox virus, H1N1 influenza, dengue virus, Zika virus, and hepatitis B and C, are examined in detail, with an emphasis on therapeutic interventions and clinical trial outcomes. Tabulated data summarize the efficacy, target mechanisms, and trial phases of key repurposed drugs. Additionally, the integration of emerging technologies, particularly artificial intelligence and machine learning, has enhanced the identification of novel drug-virus interactions, thereby increasing the precision of repurposing strategies. The paradigm shift toward host-targeted therapies further offers an alternative approach by disrupting host factors essential for viral replication. Despite significant progress, clinical challenges such as drug resistance, dosing optimization, and safety concerns persist. Overall, this review underscores the evolving role of repurposed drugs as a strategic asset in combating current and future viral pandemics through an integrated, evidence-based framework. Unlike many prior reviews that focus on single pathogens or early in silico candidate lists, we (i) benchmarked computational predictions against Phase II–IV clinical outcomes and real-world evidence, (ii) compared host-directed versus virus-directed repurposing strategies across multiple viral families, and (iii) integrated organ-specific toxicity constraints to explain translational attrition and guide future trial design.
Indexed as
Identifiers
41879902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.